# Icahn School of Medicine at Mount Sinai: Phase 2 study started recruiting, 150 planned (Post-acute Sequelae of COVID-19, Long COVID)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Sponsor type | Academic and hospital |
| Study | SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction |
| NCT ID | NCT07597902 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Post-acute Sequelae of COVID-19; Long COVID |
| Intervention types | drug |
| Target enrollment | 150 |
| Site countries | United States |
| Posted | 2026-05-19 |
| Planned start | 2026-10-20 |
| Event | Started recruiting |
| Event date | 2026-10-20 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.
- 150 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07597902). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.